NDA 219792 · Ucb INC
Kygevvi
Doxecitine, Doxribtimine · Oral
NovelBreakthrough therapyPriority reviewOrphanCDER novel approval, Nov 3, 2025: To treat thymidine kinase 2 deficiency in patients who start to show symptoms when they are 12 years old or younger
Last checked: Nov 19, 2026Latest source record: Nov 3, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Nov 3, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2
0 Phase 3, 1 recruiting
FAERS reports
34
13 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 16, 2026.
KYGEVVI is indicated for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years. KYGEVVI is a combination of doxecitine and doxribtimine, both pyrimidine nucleosides, indicated for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years. ( 1 )
Mechanism: Administration of KYGEVVI is intended to incorporate the pyrimidine nucleosides, deoxycytidine and deoxythymidine, into skeletal muscle mitochondrial deoxyribonucleic acid (DNA). This action restores mitochondrial DNA copy number in TK2d mutant mice.
Therapeutic areas: Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 3, 2025 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLetterLabelReview
1 products under this application
- KYGEVVI · DOXECITINE 2GM/PACKET; DOXRIBTIMINE 2GM/PACKET · FOR SOLUTION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Doxecitine" as an intervention, any sponsor and status, largest first.
NCT03845712 · 47 participants · Start Jul 5, 2019 · Primary completion Aug 26, 2026
Drug: doxecitine and doxribtimine · For: Thymidine Kinase 2 Deficiency
Sites: New York, New York; Haifa, Israel; Holon, Israel · 8 sites in all
Cristina Domínguez GonzálezAcademic, hospital or other
NCT06754098 · 15 participants (planned) · Start Jan 1, 2025 · Primary completion Jan 31, 2027
Drug: Doxecitine and Doxribtimine · For: Thymidine Kinase 2 (TK2 ) Deficiency; Mitochondrial Myopathies
Sites: Madrid, Spain
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea11
- off label use11
- vomiting6
- femur fracture5
- gastrostomy5
- pneumonia5
- tracheostomy5
- bradycardia3
- illness3
- tracheitis3
- anxiety2
- asthenia2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2026 | 34 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacokinetics and Safety of a 1:1 Mixture of Doxecitine and Doxribtimine: Open-label Phase 1 Single Ascending Dose and Food Effect Studies in Healthy Adults.
Mittur A, VanMeter SA, Orujov E, et al. · Clin Ther 2024 · Clinical Trial, Phase I
- Effect of Renal Impairment on the Pharmacokinetics and Safety of Doxecitine and Doxribtimine: A Single-Dose Phase 1 Study.
Mittur A, VanMeter SA · Clin Pharmacol Drug Dev 2026 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
Sponsor: UCB
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.